Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below Fifty Day Moving Average - What's Next?

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $9.11 and traded as low as $6.96. Seres Therapeutics shares last traded at $7.13, with a volume of 62,725 shares traded.

Analyst Ratings Changes

MCRB has been the topic of several recent analyst reports. Chardan Capital reiterated a "neutral" rating and set a $6.00 target price (up from $1.25) on shares of Seres Therapeutics in a research report on Thursday, May 8th. The Goldman Sachs Group reduced their target price on Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating on the stock in a research report on Friday, March 14th. Finally, Wall Street Zen upgraded Seres Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, May 9th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $73.67.

Seres Therapeutics Stock Performance

The business has a fifty day moving average price of $8.98 and a 200 day moving average price of $13.76. The company has a market capitalization of $63.39 million, a PE ratio of -31.56 and a beta of 2.89.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biotechnology company reported ($2.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($1.57). Research analysts forecast that Seres Therapeutics, Inc. will post -0.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Seres Therapeutics

Hedge funds have recently bought and sold shares of the business. Avantax Advisory Services Inc. grew its stake in Seres Therapeutics by 170.9% during the 4th quarter. Avantax Advisory Services Inc. now owns 45,179 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 28,500 shares in the last quarter. Jane Street Group LLC grew its stake in Seres Therapeutics by 181.4% during the 4th quarter. Jane Street Group LLC now owns 58,736 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 37,866 shares in the last quarter. SBI Securities Co. Ltd. grew its stake in Seres Therapeutics by 221.8% during the 1st quarter. SBI Securities Co. Ltd. now owns 69,664 shares of the biotechnology company's stock valued at $49,000 after purchasing an additional 48,013 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Seres Therapeutics by 40.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 21,679 shares in the last quarter. Finally, Invesco Ltd. grew its stake in Seres Therapeutics by 193.2% during the 1st quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company's stock valued at $96,000 after purchasing an additional 89,995 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company's stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.